| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xiuxia Yuan, Peifen Zhang, Yaping Wang, Yafei Liu, Xue Li, Bachoo Upshant Kumar, Gangrui Hei, Luxian Lv, Xu-Feng Huang, Xiaoduo Fan, Xueqin Son. Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. Schizophrenia research. vol 201. 2019-05-20. PMID:29859859. |
this study was to examine the alterations in metabolic parameters, anti-oxidant superoxide dismutase (sod), inflammatory marker high-sensitivity c-reactive protein (hs-crp) and microbiota after 24-week risperidone treatment in drug naïve, normal weight, first episode schizophrenia patients; the study further examined the relationship between metabolic changes and changes in microbiota. |
2019-05-20 |
2023-08-13 |
Not clear |
| Bunta Yoshimura, Kojiro Sato, Shinji Sakamoto, Masaru Tsukahara, Yusaku Yoshimura, Ryuhei S. Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. Psychopharmacology. vol 236. issue 2. 2019-04-25. PMID:30443794. |
incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. |
2019-04-25 |
2023-08-13 |
Not clear |
| Shin Ono, Takuro Sugai, Yutaro Suzuki, Manabu Yamazaki, Kazutaka Shimoda, Takao Mori, Yuji Ozeki, Hiroshi Matsuda, Norio Sugawara, Norio Yasui-Furukori, Kurefu Okamoto, Toyoaki Sagae, Toshiyuki Somey. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. BMC psychiatry. vol 18. issue 1. 2019-04-19. PMID:29879941. |
the aim of the present study was to compare the levels of high-density lipoprotein (hdl)-cholesterol in japanese schizophrenia patients medicated with olanzapine, risperidone, or aripiprazole monotherapy. |
2019-04-19 |
2023-08-13 |
Not clear |
| Alireza Ghajar, Faezeh Gholamian, Maryam Tabatabei-Motlagh, Mohsen Afarideh, Farzin Rezaei, Maryam Ghazizadeh-Hashemi, Shahin Akhondzade. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Human psychopharmacology. vol 33. issue 4. 2019-04-16. PMID:29901250. |
citicoline (cdp-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. |
2019-04-16 |
2023-08-13 |
Not clear |
| Lingyue Ma, Xiaodan Zhang, Qian Xiang, Shuang Zhou, Nan Zhao, Qiufen Xie, Xia Zhao, Ying Zhou, Yimin Cu. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis. Basic & clinical pharmacology & toxicology. vol 124. issue 1. 2019-04-16. PMID:30103286. |
the effect of risperidone treatment in patients with schizophrenia varies according to the dopamine receptor genes. |
2019-04-16 |
2023-08-13 |
Not clear |
| Mohsin Qureshi, Mohd Aqil, Syed Sarim Imam, Abdul Ahad, Yasmin Sultan. Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study. Current drug delivery. vol 16. issue 2. 2019-04-01. PMID:30317997. |
the present work was designed to explore the efficacy of neuroactive drug (risperidone) loaded chitosan lipid nanoparticle (ris-ch-lnps) to enhance the bioactivity in schizophrenia via the nasal route. |
2019-04-01 |
2023-08-13 |
Not clear |
| Szu-Jui Fan, Ning Lu, Hui-Chih Chang, Chao-Hsiun Tang, Kuo-Cherh Huan. Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan. International clinical psychopharmacology. vol 33. issue 4. 2019-03-27. PMID:29489495. |
health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in taiwan. |
2019-03-27 |
2023-08-13 |
Not clear |
| Szu-Jui Fan, Ning Lu, Hui-Chih Chang, Chao-Hsiun Tang, Kuo-Cherh Huan. Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan. International clinical psychopharmacology. vol 33. issue 4. 2019-03-27. PMID:29489495. |
the aim of the nationwide retrospective matched cohort study was to evaluate health service utilization and medical costs between patients with schizophrenia who received long-acting injectable (lai) risperidone and those who took risperidone orally. |
2019-03-27 |
2023-08-13 |
Not clear |
| Szu-Jui Fan, Ning Lu, Hui-Chih Chang, Chao-Hsiun Tang, Kuo-Cherh Huan. Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan. International clinical psychopharmacology. vol 33. issue 4. 2019-03-27. PMID:29489495. |
in summary, this study suggested that patients with schizophrenia treated with lai risperidone had shorter lengths of stay, higher medical costs largely because of increased utilization of outpatient service and hospital admissions, compared with those who took risperidone orally. |
2019-03-27 |
2023-08-13 |
Not clear |
| Kyle Lenz, Judy Perry-Rose, Mujeeb Sha. Delayed galactorrhea after discontinuation of risperidone in a schizophrenia patient. Asian journal of psychiatry. vol 30. 2019-03-15. PMID:28837941. |
delayed galactorrhea after discontinuation of risperidone in a schizophrenia patient. |
2019-03-15 |
2023-08-13 |
Not clear |
| Marcos Leite Santoro, Vanessa Ota, Simone de Jong, Cristiano Noto, Leticia M Spindola, Fernanda Talarico, Eduardo Gouvea, Sang Hyuck Lee, Patricia Moretti, Charles Curtis, Hamel Patel, Stephen Newhouse, Carolina Muniz Carvalho, Ary Gadelha, Quirino Cordeiro, Rodrigo Affonseca Bressan, Sintia Iole Belangero, Gerome Bree. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. Translational psychiatry. vol 8. issue 1. 2019-03-14. PMID:30171181. |
in this study, we aimed to test if the schizophrenia (scz) polygenic risk score (prs) was associated with clinical symptoms in (a) the first episode of psychosis pre-treatment (fep), (b) at nine weeks after initiation of risperidone treatment (fep-9w) and (c) with the response to risperidone. |
2019-03-14 |
2023-08-13 |
Not clear |
| Ataru Inagak. [Safety of Long-acting Injectable Antipsychotics Is Long-acting Injection a High-risk Treatment Option?]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 118. issue 8. 2019-03-13. PMID:30620477. |
this number was not higher than that of those on oral antipsychotics (5.00-8.55/1,000 person-years) ; 2) the mortality of those on pal-p in clinical trials (3.56/1,000 person-years) was not higher than that on the other lais (6.34-7.95/ 1,000 person-years); 3) the mortality of those on pal-p observed in the eppv (equivalent to 0.22% per three months) was similar to the three-month mortality observed in the pmss of risperidone lai, oral paliperidone, or oral blonanserin (0.19-0.31%); and 4) based on data of the cohort studies, the four-month mortality of those with schizophrenia was estimated at 0.35-0.68%. |
2019-03-13 |
2023-08-13 |
Not clear |
| Benneth Ben-Azu, Itivere Adrian Omogbiya, Adegbuyi Oladele Aderibigbe, Solomon Umukoro, Abayomi Mayowa Ajayi, Ezekiel O Iwalew. Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways. Brain research bulletin. vol 139. 2019-03-12. PMID:29425796. |
our data further suggests that adjunctive oral administration of doxycycline may augment the therapeutic efficacy of risperidone particularly for the treatment of negative and cognitive symptoms associated with schizophrenia. |
2019-03-12 |
2023-08-13 |
mouse |
| Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Atsuhiko Takay. Treatment retention of risperidone long-acting injection in patients with early-onset schizophrenia in Japan. Asian journal of psychiatry. vol 27. 2019-03-11. PMID:28558887. |
treatment retention of risperidone long-acting injection in patients with early-onset schizophrenia in japan. |
2019-03-11 |
2023-08-13 |
Not clear |
| Wei Zhou, Wushao Chang, Yucai Yan, Lu Shen, Wenqiang Li, Zhenghui Yi, Shengying Qi. Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients. Neuroscience letters. vol 683. 2019-03-11. PMID:30081060. |
the aim of the study was to investigate the association of 14 single nucleotide polymorphisms (snps) selected from htr3c, htr3d, htr5a and htr6 with risperidone response in 201 han chinese schizophrenia patients. |
2019-03-11 |
2023-08-13 |
human |
| Soichi Kono, Itaru Miura, Sachie Oshima, Masayuki Hikita, Akira Wada, Rieko Suzuki, Shin-Ichi Niwa, Hirooki Yab. Frontal activity measured by near-infrared spectroscopy in patients taking different atypical antipsychotic drugs: A cross-sectional study. Psychiatry research. Neuroimaging. vol 273. 2019-03-05. PMID:29329742. |
using near-infrared spectroscopy, we examined changes in the concentration of oxygenated hemoglobin ([oxy-hb]) in the frontal lobe during a verbal fluency task in 20 patients with schizophrenia (10 patients each receiving olanzapine [olz] and risperidone [ris]) and 10 healthy controls. |
2019-03-05 |
2023-08-13 |
Not clear |
| Yusaku Yoshimura, Toshihiko Takeda, Yoshiki Kishi, Toshiki Harada, Akira Nomura, Kenji Washida, Bunta Yoshimura, Kojiro Sato, Yuji Yada, Shozo Aok. Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. International clinical psychopharmacology. vol 33. issue 3. 2019-02-25. PMID:29406406. |
two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. |
2019-02-25 |
2023-08-13 |
Not clear |
| Yusaku Yoshimura, Toshihiko Takeda, Yoshiki Kishi, Toshiki Harada, Akira Nomura, Kenji Washida, Bunta Yoshimura, Kojiro Sato, Yuji Yada, Shozo Aok. Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. International clinical psychopharmacology. vol 33. issue 3. 2019-02-25. PMID:29406406. |
this study aimed to assess the comparative effectiveness of risperidone (ris) versus aripiprazole (arp) in patients with recent-onset or chronic schizophrenia during maintenance treatment and to examine the interaction between illness duration and the effectiveness of the treatment. |
2019-02-25 |
2023-08-13 |
Not clear |
| Lulu Zhang, Hongbo Zheng, Rengrong Wu, Furong Zhu, Thomas R Kosten, Xiang-Yang Zhang, Jingping Zha. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Progress in neuro-psychopharmacology & biological psychiatry. vol 85. 2019-01-17. PMID:29678772. |
minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: association with pro-inflammatory cytokine levels. |
2019-01-17 |
2023-08-13 |
Not clear |
| Leslie Citrom. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert review of neurotherapeutics. vol 17. issue 10. 2019-01-03. PMID:28832262. |
approved indications have expanded beyond schizophrenia to also include bipolar maintenance (risperidone microspheres and aripiprazole monohydrate) and schizoaffective disorder (paliperidone palmitate monthly). |
2019-01-03 |
2023-08-13 |
Not clear |